<DOC>
	<DOCNO>NCT00006244</DOCNO>
	<brief_summary>This phase II trial study effectiveness melphalan , peripheral stem cell transplantation , interleukin-2 follow interferon alfa treat patient advanced multiple myeloma ( MM ) . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Interleukin-2 ( IL2 ) may stimulate person 's white blood cell kill multiple myeloma cell . Interferon alfa may interfere growth cancer cell</brief_summary>
	<brief_title>Melphalan , Peripheral Stem Cell Transplantation , Interleukin-2 Followed Interferon Alfa Treating Patients With Advanced Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate initial response therapy , time disease progression , overall survival MM patient treat melphalan , IL2- incubate peripheral blood stem cell , sequential IL2 . SECONDARY OBJECTIVES : I . Evaluate grade 3-4 toxicity encounter young ( &lt; 56 year old ) old ( &gt; 56 year old ) advance multiple myeloma patient treat melphalan , IL2-incubated peripheral blood stem cell , sequential IL2 . OUTLINE : Patients receive melphalan intravenously ( IV ) 2-3 hour day -2 infusion IL-2-treated autologous syngeneic peripheral blood stem cell day 0 . Beginning day 0 , patient also receive IL-2 IV continuously 5 day follow 2 day . Treatment IL-2 repeat weekly 4 week . Beginning 1 month later , patient undergo maintenance therapy comprise interferon alfa subcutaneously ( SC ) 3 time week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patient must less 70 year old Patients advance Multiple Myeloma meet eligibility requirement mobilization/debulking Cytoxan/VP16/GCSF , Cytoxan/Taxol/GCSF , Cytoxan/GCSF ( accord protocol 506.03 ) ; clinically indicate low dose cytoxan 4g/m2 may use mobilization base attend 's discretion ; also , patient previously collect PBSC sufficient number past meet eligibility requirement , may enter study approval PI Patients advance Multiple Myeloma identical syngeneic twin donation PBSCs Patients advance Multiple Myeloma diagnose initially stage II III disease stage I disease progressed initial therapy fail respond therapy Syngeneic Donor Inclusion : Donor patient adequate documentation donor recipient syngeneic ; include ABO typing , HLA type VNTR study Donor &gt; 20 kg Donor meet eligibility donate accord Standard Practice Guidelines Patient 's age &gt; = 70 Karnofsky score less 80 A leave ventricular ejection fraction le 50 % ; Patients congestive heart disease , history myocardial infarction ( MI ) , coronary artery disease arrhythmia history Total bilirubin &gt; 1.5 mg/ml ( unless history Gilbert 's disease ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &gt; 2 x upper limit normal Estimated creatinine clearance &lt; 60 ml/min creatinine serum &gt; 2.0 mg/dl Pregnancy Seropositivity human immunodeficiency virus Patients give inform consent Secondary malignancy basal cell carcinoma skin carcinoma situ within last five year History seizures requirement medicine , haldol , control mental disorder Concurrent need corticosteroid therapy Active connective tissue disease Pleural effusion , pericardial effusion ascites Patients allergic gentamicin Patients positive PCR hepatitis C hepatitis B Patients hypersensitivity E. coli derive preparation Patients systemic infection time IL2 therapy Patients previously 50 % pelvic area irradiate Patients pulmonary function test show diffusion capacity ( correct ) &lt; 60 % , and/or forced expiratory volume 1 second ( FEV1 ) &lt; 65 % predict</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>